Axon Enterprise, Inc. (NASDAQ:AXON) is Ashford Capital Management Inc.'s 3rd Largest Position

Ashford Capital Management Inc. cut its holdings in Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 36.6% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 55,021 shares of the biotechnology company's stock after selling 31,695 shares during the period. Axon Enterprise accounts for about 3.9% of Ashford Capital Management Inc.'s holdings, making the stock its 3rd biggest position. Ashford Capital Management Inc. owned 0.07% of Axon Enterprise worth $32,700,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the business. New Wave Wealth Advisors LLC acquired a new position in Axon Enterprise in the fourth quarter valued at $40,000. Y.D. More Investments Ltd purchased a new stake in Axon Enterprise in the 4th quarter valued at about $45,000. Stonebridge Financial Group LLC acquired a new position in shares of Axon Enterprise during the 4th quarter valued at about $53,000. GPS Wealth Strategies Group LLC lifted its holdings in shares of Axon Enterprise by 74.1% during the 4th quarter. GPS Wealth Strategies Group LLC now owns 94 shares of the biotechnology company's stock worth $56,000 after acquiring an additional 40 shares during the period. Finally, Berbice Capital Management LLC purchased a new position in shares of Axon Enterprise during the 4th quarter worth about $59,000. Hedge funds and other institutional investors own 79.08% of the company's stock.

Axon Enterprise Stock Up 1.2%

NASDAQ AXON opened at $742.32 on Tuesday. The company has a quick ratio of 2.63, a current ratio of 2.96 and a debt-to-equity ratio of 0.32. Axon Enterprise, Inc. has a fifty-two week low of $273.52 and a fifty-two week high of $742.34. The business has a 50 day moving average price of $588.30 and a two-hundred day moving average price of $597.92. The stock has a market cap of $57.79 billion, a PE ratio of 191.81, a P/E/G ratio of 5.17 and a beta of 1.24.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last announced its earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.07. The business had revenue of $603.63 million during the quarter, compared to the consensus estimate of $585.67 million. Axon Enterprise had a net margin of 15.37% and a return on equity of 7.50%. The business's quarterly revenue was up 31.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.15 earnings per share. As a group, sell-side analysts predict that Axon Enterprise, Inc. will post 5.8 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on AXON. The Goldman Sachs Group boosted their target price on shares of Axon Enterprise from $730.00 to $830.00 and gave the company a "buy" rating in a report on Wednesday, May 14th. Needham & Company LLC upped their price objective on Axon Enterprise from $600.00 to $750.00 and gave the stock a "buy" rating in a report on Thursday, May 8th. Northcoast Research cut Axon Enterprise from a "buy" rating to a "neutral" rating in a report on Wednesday, February 19th. JMP Securities reissued an "outperform" rating on shares of Axon Enterprise in a research report on Tuesday, February 4th. Finally, Barclays raised their price objective on Axon Enterprise from $726.00 to $735.00 and gave the stock an "overweight" rating in a report on Friday, May 9th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $652.73.

Insider Buying and Selling at Axon Enterprise

In related news, President Joshua Isner sold 9,000 shares of the business's stock in a transaction dated Monday, May 12th. The stock was sold at an average price of $683.31, for a total value of $6,149,790.00. Following the transaction, the president now owns 308,714 shares in the company, valued at approximately $210,947,363.34. The trade was a 2.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Jeri Williams sold 307 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $552.72, for a total value of $169,685.04. Following the sale, the director now owns 1,627 shares of the company's stock, valued at approximately $899,275.44. This trade represents a 15.87% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 23,764 shares of company stock valued at $14,856,635 in the last ninety days. Insiders own 4.40% of the company's stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.

Want to see what other hedge funds are holding AXON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axon Enterprise, Inc. (NASDAQ:AXON - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.